Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

SP up a bit this morning... all looking good so far!

Doing ok for now..just waiting for the good news

Awesome! The good news has arrived... prelude to approval... looking good!

well done sky - in here myself also

a huge market awaits ple now and would suggest this will continue to trend north - many years of r&d in coming to rapid fruition here - great time to buy in & for any that like charts.....

http://www.barchart.com/quotes/stocks/PLE.LS

Looks good gibby and skyhigh.

Positive CHMP Opinion

RNS


RNS Number : 5437O

Plethora Solutions Holdings PLC

20 September 2013










20 September 2013



Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Positive CHMP Opinion

for PSD502 a treatment for premature ejaculation



Plethora Solutions Holdings plc (AIM: PLE) announces that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending European Commission (EC) approval for PSD502 (known in the Marketing Authorisation Application as "Lidocaine Prilocaine Plethora") for the treatment of primary premature ejaculation in adult men.



A CHMP positive opinion is one of the final steps before Marketing Authorisation is granted by the European Commission. The CHMP's positive recommendation will be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union. Plethora anticipates a final decision from the EC shortly, as this usually occurs approximately 60 days after a CHMP recommendation. Plethora anticipates that when approved by the EC PSD502 will be launched in Europe as soon as practicable thereafter.



PSD502 is a treatment for premature ejaculation, comprising a combination of lidocaine and prilocaine in a spray formulation. Clinical studies have demonstrated that PSD502 is effective in treating premature ejaculation with an acceptable safety profile.



Ronald Openshaw, CEO Plethora said:



"Today's announcement by the CHMP is the key opinion the Company has been seeking to obtain European approval. We are delighted by today's news after such a significant period to reach this milestone.



Premature ejaculation is a highly distressing condition for patients and their partners and there remains a significant unmet medical need given the lack of effective products to treat it.



Our efforts are now focussed on achieving a European launch post EC approval and on the US filing with the FDA. The Company's goal is to see PSD502 available internationally to improve the lives of so many couples."





-Ends-

well done dc didn't realise you had these - and thanks - expecting much more here the global market is huge and affects normal peoples every day lives and not some mine or oil field in the middle of some war torn country somewhere

the latest ple personnel addition and other items strongly suggest take over at some point - personally holding out for a 3 figure sp especially after ema rubber stamping (but might sell some at 50p lols)

this is a very good buy in level and be interesting to see what Monday holds as most short term traders already exited Friday - likely they will be back but would suggest their re-buy price should be much higher
looking at the longer term though very good imo
cheers

looking vey good. :-))

good stuff dc - looking fwd to tomorrow & beyond - huge potential here........

Extract from an article in 2012:

From an inventor of Viagra, a spray to help love last beyond a moment

He put smiles on millions of faces when he helped invent Viagra. Now the brains behind the little blue pills claims to have done it again.

Mike Wyllie, one of the team of scientists who developed Viagra in the 1990s, has created a drug that tackles premature ejaculation.

He predicts the spray-on medication, designed to prolong the joy of sex for millions of sufferers and their partners, is likely to become ‘the next blockbuster’ drug.

Premature ejaculation affects more than one in four men – making it more common than the impotence tackled by Viagra. Most are too embarrassed to seek help and when they do, treatments are generally limited to powerful anti-depressants and counselling.

There is one pill specifically designed to treat the problem but it is expensive and not widely available in the UK. In contrast, it is hoped the spray, called Tempe, which could be on sale within months, will be cheap enough for prescription on the NHS.

In trials, some men using the spray ahead of sex lasted up to eight times longer. But the drug is generally thought to treble a man’s ‘staying power’.

Dr Wyllie, formerly of pharmaceutical giant Pfizer and now chief scientific officer of British biotech firm Plethora Solutions, calls Tempe his ‘new Viagra’.

It is as much appreciated by partners as by the sufferers,’ he said. ‘I feel in many respects the clinical data are as impressive as Viagra’s.’

Premature ejaculation can wreck self-esteem, make it difficult to form relationships and, at its worst, can make it impossible for partners to become pregnant. While the exact causes are unclear, it is thought over-sensitivity contributes to the problem.

Tempe contains low doses of two anaesthetics which help give a man more control, without creating an uncomfortable numbing sensation.

It takes about five minutes to get to work, but those who do not wish to give away their secret will be pleased to know it can be sprayed on up to two hours before sex.

A pocket-sized can will last a year, if a man has sex five or six times a month.

The average European man has staying power of six minutes, said Dr John Dean, an expert who helped run the trials. The drug is aimed at those who struggle to last a minute and is not thought to provide much extra time to those who do not have a problem.

Plethora Solutions is confident its application for a licence to sell Tempe across Europe will be approved, meaning the drug could be on sale by autumn next year. Dr Wyllie, who is also assistant editor of the British Journal of Urology, said: ‘It could be the next blockbuster, the potential is enormous.’

:-)) thanks for that info.

Patience is needed with these drug companies. A huge risk in the early days but if all the phases/tests go in the companies favour there is huge reward for the shareholders. A few of them starting to show good potential.

dc the wait is over now which is why ple flying - gl

in the newspapers this is going to be huge as affects real people everywhere globally from the inventor of Viagra now working for ple:

daily mail

http://www.dailymail.co.uk/news/article-2429658/The-inventor-Viagra-gives-men-new-lift-Man-sex-wonder-drug-creates-spray-combat-premature-ejaculation.html#ixzz2fhBNEJj3

PUBLISHED: 00:19, 23 September 2013 | UPDATED: 00:20, 23 September 2013






89 shares

5

View
comments


Help: The Tempe spray could be in bathroom cabinets as early as next year
Help: The Tempe spray could be in bathroom cabinets as early as next year

He has already helped prevent millions of men from flopping in the bedroom.

Now one of the inventors of Viagra claims to have a drug that will help many more experience the joy of sex.

Mike Wyllie, one of the team of scientists who developed Viagra in the Nineties, is poised to launch a treatment for premature ejaculation.


Tempe, a spray-on medication, has been judged safe and effective by the European Medicines Agency and is expected in bedroom cabinets early next year.

Premature ejaculation is a problem that affects at least one in four men, making it more common than the impotence caused by Viagra.

In trials, men who used the spray ahead of sex lasted on average five times longer.

Women also benefited from longer love making, with both sexes expressing greater satisfaction with their sex life.

Dr Wyllie, formerly of pharmaceutical giant Pfizer and now of small British biotech firm Plethora Solutions, said: ‘Premature ejaculation doesn’t just make the patient feel bad.

‘It does affect the partner and can completely destroy relationships. I feel this could save relationships.’

Premature ejaculation can wreck self-esteem, make it difficult to form and maintain relationships and, at its worst, can make it impossible for partner to become pregnant.

Despite its toll, there is just one pill specifically designed to tackle the problem but it is expensive and not widely available in the UK.

The exact causes are unclear but it is thought over-sensitivity is part of the problem.

The Tempe spray contains low doses of two anaesthetics which help give a man more control. It only takes around five minutes to get work, although those who like to be spontaneous will be pleased to know it can be sprayed on up to two hours before sex.




More...
Revealed, the sleepy country town that has been named the Viagra capital of England
Why is the NHS ignoring erectile dysfunction when it is the number one sex problem for men?


A pocket-sized can will last a year, if a man has sex five or six times a month.

However, some of those who tested the drug experienced side-effects, including burning sensations and headaches.

And some fear that using a drug as a ‘quick fix’ will prevent couples from confronting the stress, anxiety and relationship troubles that could be at the heart of the problem.


Research: Dr Wyllie helped develop Viagra, pictured, which made £1.3billion worldwide last year
Research: Dr Wyllie helped develop Viagra, pictured, which made £1.3billion worldwide last year


Tempe will only be available on private prescription initially. But it is hoped that it will be judged cheap enough in the long-run to be prescribed to some men on the NHS.

With sales of Viagra worth £1.3billion a year worldwide, the new drug has the potential to be a blockbuster.

However, Dr Wyllie will not receive any royalties from the sales and only has a very small holding in Plethora Solutions.

He says he was motivated by scientific curiosity and that the launch will be a triumph for a small British company that lacks the manpower and resources of the big players in the market.


Tempe’s preliminary approval for sale EU is expected to be rubber-stamped by the European Commission in the next few weeks.

John Dean, one of Britain’s leading experts on male sexual problems and a past president of the International Society for Sexual Medicine, said: ‘Whilst premature ejaculation is not a life-threatening condition, its consequences can be serious.

‘This is a chronic, debilitating problem, affecting both men and their partners.’


Read more: http://www.dailymail.co.uk/news/article-2429658/The-inventor-Viagra-gives-men-new-lift-Man-sex-wonder-drug-creates-spray-combat-premature-ejaculation.html#ixzz2fhDFTW4H
Follow us: @MailOnline on Twitter | DailyMail on Facebook

Another good day

Plethora Solutions (LON:PLE) is still very much in the sights of small cap investors. Today, punters were speculating about a possible takeover from drug giant Pfizer following Friday’s news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given its treatment for premature ejaculation their seal of approval.

The AIM-listed company received a “positive opinion” from the committee for PSD502 in one of the last few steps before marketing authorisation is granted by the European Commission (EC).

The decision will be reviewed by the EC, which has the power to give medicines the green light in Europe. It thinks a final decision will arrive shortly from the EC – typically around 60 days after a CHMP recommendation.

Before todays rise -


Plethora Solutions Plc (PLE): Target Towards 12p

http://www.directorstalk.com/plethora-solutions-plc-ple-target-towards-12p-despite-recent-gains-chart-and-commentary/

In shares today - watch the cash position as they are burning it.

INTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2013

RNS


RNS Number : 1858P

Plethora Solutions Holdings PLC

30 September 2013












PLETHORA SOLUTIONS HOLDINGS PLC

("Plethora" or the "Company")

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2013



Plethora is pleased to announce its interim results for the six months ended 30 June 2013.



Highlights



· Refocusing of business solely on PSD502



· Successful placing raising £2.1 million together with debt restructuring



· Now responsible for regulatory and commercial development of PSD502 globally



· Strengthening of Plethora board



· A CHMP positive opinion in relation to PSD502 approval for European Union in September 2013



Ronald Openshaw, CEO of Plethora said:



"2013 has so far been an exceptional year for Plethora, We have focussed the Group's full effort on PSD502; expanded our geographic interest in the product; commenced work on the filing with the FDA in the United States and achieved a milestone in the European regulatory process. Our efforts are to ensure that PSD502 is brought to market to ease the distress of so many couples".





- Ends -

Moving up nice, on a poor markets day.

probably reverse a bit more as from 20th September it is approximately 60 days after a CHMP recommendation to final decision - then imo watch it really fly on receipt of that